Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Pulmonary Hypertension, March 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 146 articles: HTML format

Single Articles

1. LYU Y, Nagra R, DeLonais-Parker AR, Lentine KL, et al
   Association of pre-transplant pulmonary hypertension and post-transplant major adverse cardiovascular events in kidney transplant recipients: a retrospective study.
   BMC Nephrol. 2026 Feb 27. doi: 10.1186/s12882-026-04832.
   PubMed    
   Abstract available
   
   

2. LAI Y, He L, Cai H, Zhou W, et al
   Feasibility and safety of right heart catheterization via median cubital vein in patients with pulmonary hypertension.
   BMC Cardiovasc Disord. 2026 Feb 27. doi: 10.1186/s12872-026-05604.
   PubMed    
   
   
   

3. KIELY DG, Wort SJ, Funes D, Fernandez Delgado M, et al
   Incidence and prevalence of pulmonary hypertension in chronic lung disease: insights from a retrospective cohort study using a UK nationwide health database.
   BMJ Open. 2026;16:e108228.
   PubMed    
   Abstract available
   
   

4. TOSUN D, Bingol I, Akcay N
   Lamp Oil Poisoning: Pulmonary Hypertension Following Oil Aspiration Successfully Treated with Inhaled Nitric Oxide.
   Klin Padiatr. 2026 Feb 27. doi: 10.1055/a-2814-3185.
   PubMed    
   
   
   

5. J WHITLEY WN, Millis RM
   Epigenetic Drivers of Pulmonary Hypertension: Environment Meets Genome.
   Cureus. 2026;18:e104241.
   PubMed    
   Abstract available
   
   

6. TORRES YP, Aristizabal-Pachon AF, Otero L
   TRPC Channels as Mediators of Hypoxia-Induced Pulmonary Hypertension in Obstructive Sleep Apnea.
   Int J Mol Sci. 2026;27:1861.
   PubMed    
   Abstract available
   
   

7. BESTE NC, Bunck AC, Kottlors J, Reimer RPWM, et al
   Pulmonary Artery and Vein Morphology as an Imaging Biomarker for the Diagnosis of Pulmonary Hypertension.
   Diagnostics (Basel). 2026;16:619.
   PubMed    
   Abstract available
   
   

8. SINGH Y, Nath S, Gahlaut S, Chan B, et al
   Physiology-Based Diagnosis and Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension (BPD-PH).
   Children (Basel). 2026;13:272.
   PubMed    
   Abstract available
   
   

9. PERRET PL, Kim JH, Winkler A, Ott C, et al
   Dysregulated Klotho and FGF23 signaling aggravates vascular remodeling in age-related pulmonary hypertension.
   Cardiovasc Res. 2026 Feb 27:cvag048. doi: 10.1093.
   PubMed    
   Abstract available
   
   

10. TREES C
    Evidence-Based Management of Persistent Pulmonary Hypertension.
    Neonatal Netw. 2026;45:9-17.
    PubMed    
    Abstract available
    
    

11. SCHMERMUND BN, Rieth AJ, Rademann M, Wilke PC, et al
    Manual long axis strain compared to automated feature-tracking deformation imaging for identification of masked left heart involvement in pulmonary hypertension.
    Int J Cardiovasc Imaging. 2026 Feb 26. doi: 10.1007/s10554-026-03664.
    PubMed    
    
    
    

12. HU C, Chen Z, Lv L, Zhu Y, et al
    Clinical Application of Inhaled Nitric Oxide in Conditions of Excessive Right Heart Load: A Review from Neonatal Pulmonary Hypertension to Perioperative Cardiac Surgery Management.
    J Cardiovasc Dev Dis. 2026;13:81.
    PubMed    
    Abstract available
    
    

13. IMTIAZ H, Mohammed AS, Mondal A, Kodali LSM, et al
    Predictors of Secondary Pulmonary Hypertension-Related Hospitalizations and Subsequent Mortality in Adults with Obstructive Sleep Apnea.
    Diseases. 2026;14:73.
    PubMed    
    Abstract available
    
    

14. KIRIS A, Zhang P, Bronk P, Prins KW, et al
    Supraventricular Arrhythmias in Pulmonary Hypertension: A Comprehensive Review From Preclinical Evidence to Clinical Practice.
    Pulm Circ. 2026;16:e70268.
    PubMed    
    Abstract available
    
    

15. TONG W, Cheng R, Chen X, Zhang X, et al
    Tea consumption is associated with a reduced risk of high-altitude pulmonary hypertension among high-altitude permanent inhabitants in the Tibetan population: a case-control study.
    Front Nutr. 2026;13:1732242.
    PubMed    
    Abstract available
    
    

16. CHANG WT, Garcia-Guasch L, Chan IP, Montoya-Alonso JA, et al
    Development and evaluation of a composite echocardiographic score for predicting pulmonary hypertension severity in dogs.
    J Vet Intern Med. 2026;40:aalag004.
    PubMed    
    Abstract available
    
    

17. PARIKH T, Khan SA, Rao A, Patel B, et al
    Response to "Pulmonary Hypertension as a Determinant of In-Hospital Mortality in COPD: Insights and Methodological Considerations".
    COPD. 2026;23:2631253.
    PubMed    
    
    
    

18. ZEDER K, Maron BA
    Social networks are not just for friends: Untangling care patterns in pulmonary hypertension.
    Ann Am Thorac Soc. 2026 Feb 25:aaoag003. doi: 10.1093.
    PubMed    
    
    
    

19. XIE F, Feng J, Li K, Chen Y, et al
    Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models.
    Mediators Inflamm. 2026;2026:5524066.
    PubMed    
    Abstract available
    
    

20. LI W, Zheng Y, Fan M, Sun Y, et al
    Pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study of medical staff's perspectives.
    Front Public Health. 2026;14:1740477.
    PubMed    
    Abstract available
    
    

21. BAYBUTT RC, Smith VB, Kearns DG, Stafford SB, et al
    Monocrotaline toxicity in rats: decreased lung retinol and elevated alpha-tocopherol levels in lung and liver.
    J Nutr Sci. 2026;15:e16.
    PubMed    
    Abstract available
    
    

22. BRIDI GDP, Freire da Silva B, Sobral-Alves JB, Carvalho CRF, et al
    Mechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis.
    ERJ Open Res. 2026;12:00656-2025.
    PubMed    
    Abstract available
    
    

23. YATA M, DeFrancesco TC, Bonagura JD, Papich MG, et al
    Population Pharmacokinetics of Sildenafil in Dogs With Naturally Occurring Pulmonary Hypertension.
    J Vet Pharmacol Ther. 2026 Feb 24. doi: 10.1111/jvp.70057.
    PubMed    
    Abstract available
    
    

24. LTEIF C, Wachs P, Sharma RK, Duarte JD, et al
    The role of Id genes on pulmonary hypertension development in left heart failure.
    Am Heart J Plus. 2025;61:100692.
    PubMed    
    Abstract available
    
    

25. WANG K, Fan J, Mei L
    The risk factors associated with pulmonary hypertension in patients with left heart diseases.
    Medicine (Baltimore). 2026;105:e47799.
    PubMed    
    Abstract available
    
    

26. PORTES AMO, de Moura AG, de Jesus Silva F, Guimaraes-Ervilha LO, et al
    Previous resistance exercise training mitigates progression of right ventricle dysfunction and remodeling in male rats with pulmonary arterial hypertension.
    Physiol Rep. 2026;14:e70786.
    PubMed    
    Abstract available
    
    

27. MOGHADAS Z, Eftekhar SP, Pourkia R, Saravi M, et al
    Pulmonary hypertension in beta thalassemia: a prospective cohort study on treatment outcomes and cardiopulmonary function.
    Acta Cardiol. 2026 Feb 23:1-6. doi: 10.1080/00015385.2025.2593662.
    PubMed    
    Abstract available
    
    

28. ISHIKAWA K, Nakao H, Shinjo D, Kubota M, et al
    Trisomy 13 as a risk factor for pulmonary hypertension induced by diazoxide.
    Ann Pediatr Cardiol. 2025;18:351-356.
    PubMed    
    Abstract available
    
    

29. EID HA, Hamdy RM, Eldosoky MA, Elhamed SSA, et al
    Unveiling MicroRNA-21 as a non-invasive diagnostic biomarker in chronic obstructive pulmonary disease-associated pulmonary hypertension: Comparative insights with NT-proBNP.
    Lung India. 2026;43:178-184.
    PubMed    
    Abstract available
    
    

30. LI Z, Li H, Qiao W, Yu S, et al
    Multi-omics dissection of high TWAS-active endothelial pathogenesis in pulmonary arterial hypertension: bridging single-cell heterogeneity, machine learning-driven biomarkers, and developmental reprogramming.
    Int J Surg. 2026;112:2650-2667.
    PubMed    
    Abstract available
    
    

31. KOZLOWSKA WU, Lomzik J, Kaminski K, Kazimierczyk R, et al
    Matrix metalloproteinases and tissue inhibitors of metalloproteinases as potential biomarkers for pulmonary arterial hypertension: A review.
    Adv Clin Exp Med. 2026;35:361-376.
    PubMed    
    Abstract available
    
    

32. BATHEJA V, Modasia B, Puri S, Meshram HS, et al
    Dual carrier status for HUPRA (hyperuricemia, pulmonary hypertension, renal failure, and alkalosis) syndrome and Wilson disease in a young dialysis patient: clinical and genetic counseling implications.
    Clin Transplant Res. 2026 Mar 5. doi: 10.4285/ctr.25.0071.
    PubMed    
    
    
    

33. LIANG Q, Wang Y, Zhang X, Guo D, et al
    Acox1 induces lipid peroxidation and metabolic shifting to promote PASMCs proliferation in hypoxia-induced pulmonary hypertension.
    Free Radic Biol Med. 2026;248:469-484.
    PubMed    
    Abstract available
    
    

34. MANSO TEJERINA P, Loaiza Q, Andres C, Margallo Iribarnegaray J, et al
    Impact of Pulmonary Veno-Occlusive Disease on Posttransplant Survival in Pulmonary Hypertension.
    Clin Transplant. 2026;40:e70493.
    PubMed    
    Abstract available
    
    

35. LIU S, Yuan H, Cao J, Cai L, et al
    Circulating fatty acid profiles and risk of pulmonary arterial hypertension: Evidence from a large prospective cohort study.
    Medicine (Baltimore). 2026;105:e47645.
    PubMed    
    Abstract available
    
    

36. ONOFRE MESF, Santos RT, Rocha NN, Caldeira DAF, et al
    Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension.
    Int J Mol Sci. 2026;27:1761.
    PubMed    
    Abstract available
    
    

37. LIN Y, Wang A, Valdez-Jasso D
    Adventitial Fibrosis and Fibroblast Mechanosensitivity Are Shaped by Sex and Hormonal Status in Pulmonary Arterial Hypertension.
    Cells. 2026;15:354.
    PubMed    
    Abstract available
    
    

38. JIANG R, Li L, Luo Y, Wang W, et al
    GM-CSF exacerbates pulmonary arterial hypertension via CCL2/CCR2-axis-mediated macrophage NLRP3 inflammasome activation.
    Int Immunopharmacol. 2026;174:116394.
    PubMed    
    Abstract available
    
    

39. SUZUKAWA A, Hemmi R, Fujiwara M, Motomura T, et al
    Repositioning lidocaine as a TMEM16A Ca(2+)-activated Cl(-) channel blocker for the treatment of pulmonary arterial hypertension.
    J Pharmacol Exp Ther. 2026;393:103799.
    PubMed    
    Abstract available
    
    

40. VERMA S, Seltzer BHS, Fisher JC, Cicalese E, et al
    Outcomes in early term neonates requiring extracorporeal membrane oxygenation.
    J Perinat Med. 2025 Oct 20. doi: 10.1515/jpm-2025-0235.
    PubMed    
    Abstract available
    
    

41. YANG MM, Liu S, Wax M 2nd, Lee S, et al
    Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis.
    Arthritis Rheumatol. 2026;78:428-437.
    PubMed    
    Abstract available
    
    

42. TORUN EG, Ozdemiroglu N, Bagrul D, Ece I, et al
    Pulmonary Artery Pulsatility Index: A Novel Marker for Risk Assessment and Prognosis in Pediatric Idiopathic Pulmonary Arterial Hypertension.
    Pediatr Cardiol. 2026;47:1788-1797.
    PubMed    
    Abstract available
    
    

43. RODRIGUEZ OGANDO A, Sabate-Rotes A, Moya Bonora A, Albert de la Torre L, et al
    Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience.
    Pediatr Cardiol. 2026;47:1572-1580.
    PubMed    
    Abstract available
    
    

44. RUESS A, Stadler S, Stark T, Berezucki E, et al
    Hemodynamic effects of cycle ergometry and low-intensity handgrip in patients with pulmonary hypertension.
    Front Med (Lausanne). 2026;13:1727173.
    PubMed    
    Abstract available
    
    

45. GIANNAKOULAS G, Preston IR, Gatzoulis MA
    Advancing the science and care of pulmonary hypertension, globally.
    Int J Cardiol Congenit Heart Dis. 2025;23:100651.
    PubMed    
    
    
    

46. YU Y, Wang Y, Yang Z, Li Z, et al
    Corrigendum to "Methyleugenol alleviates pulmonary vascular remodeling in rats with high-altitude pulmonary hypertension by improving pulmonary smooth muscle cell function" [Biomed. Pharmacother. 187 (2025) 118109].
    Biomed Pharmacother. 2026 Mar 11:119202. doi: 10.1016/j.biopha.2026.119202.
    PubMed    
    
    
    

47. CHEN J, Zhang ZL, Chen YY, Ren JH, et al
    [Use of modified balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension: a retrospective study from a single center].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:317-323.
    PubMed    
    Abstract available
    
    

48. HUANG Q, Xiong CM, Wang JZ, Zhai ZG, et al
    [Enhancing the capacity of pulmonary vascular intervention system in China: current status, opportunities, and challenges].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:251-256.
    PubMed    
    Abstract available
    
    

49. YOSHIDA K, Hosokawa K, Hiraide T, Akagi S, et al
    Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension a
    BMJ Open. 2026;16:e113430.
    PubMed    
    Abstract available
    
    

50. ZHAO J, Li N, Shi S, Zhao Y, et al
    Chronic thromboembolic pulmonary hypertension: insights from the 100 most cited papers: a bibliometric perspective.
    J Thorac Dis. 2026;18:98.
    PubMed    
    Abstract available
    
    

51. WANG WT, Li X, Wang T, Ferrizzi SA, et al
    Pulmonary Vascular Signaling in Pulmonary Hypertension: Potential Role of Endothelial Ca(2+) Signaling in Cellular Senescence and Inflammasome Activation.
    Arterioscler Thromb Vasc Biol. 2026 Mar 12. doi: 10.1161/ATVBAHA.125.322489.
    PubMed    
    Abstract available
    
    

52. ZHENG RX, Wang SZ, Tan JL, Cao XY, et al
    [Junren Bufei Yixin Granules attenuates hypoxic pulmonary hypertension via PTBP1/PKM2 signaling pathway].
    Zhongguo Zhong Yao Za Zhi. 2026;51:543-552.
    PubMed    
    Abstract available
    
    

53. TONG XL, Zhang L, Zhu J, Tong JB, et al
    [Mechanisms of Qibai Pingfei Capsules in inhibiting pyroptosis of pulmonaryartery adventitial fibroblasts via regulating NLRP3/Caspase-1/ GSDMD pathway to intervene in COPD complicated by pulmonary arterial hypertension].
    Zhongguo Zhong Yao Za Zhi. 2025;50:6892-6900.
    PubMed    
    Abstract available
    
    

54. JUTANT EM, Humbert M, Montani D, Khoury J, et al
    Pulmonary hypertension associated with nonparenchymal restrictive lung diseases.
    Eur Respir Rev. 2026;35:250187.
    PubMed    
    Abstract available
    
    

55. PANG L, Du S, Wu S, Xian Q, et al
    Genetic assessment of the causal relationship between obstructive sleep apnea and pulmonary hypertension: Mendelian randomization and meta-analysis.
    Respir Med. 2026;255:108760.
    PubMed    
    Abstract available
    
    

56. LI L, Liu B, Zhang M, Wang D, et al
    TG2 (transglutaminase 2) promotes PINK1/Parkin-dependent mitophagy in pulmonary hypertension by regulating the TRPC6.
    Free Radic Biol Med. 2026 Mar 9:S0891-5849(26)00180.
    PubMed    
    Abstract available
    
    

57. JING H, Liu J, Guo Y, Gao Z, et al
    Smooth Muscle NR4A3 Upregulation Caused by Endothelial Caveolin-1 Deficiency Mediates Vascular Remodeling and Pulmonary Hypertension.
    Free Radic Biol Med. 2026 Mar 9:S0891-5849(26)00188.
    PubMed    
    Abstract available
    
    

58. YANG MX, Wu ZZ, Wu DW, Chen MH, et al
    Role of PKM2 Tetramer in Modulating Endothelial Mitochondrial Dysfunction in a Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
    Physiol Res. 2026;75:45-53.
    PubMed    
    Abstract available
    
    

59. ZEIDAN EM, Nagarajan SA, Sydykov A, Bier J, et al
    The effect of mitoTEMPO on the development of hypoxia-induced pulmonary hypertension in male mice.
    Physiol Rep. 2026;14:e70804.
    PubMed    
    Abstract available
    
    

60. HERTIG D, Furian M, Muller J, Mayer L, et al
    Effect of short-term supplemental oxygen therapy on 6-min walk distance in highlanders at risk for pulmonary hypertension: a randomised, crossover trial.
    ERJ Open Res. 2026;12:00724-2025.
    PubMed    
    Abstract available
    
    

61. KEKEC L, Radisavljevic Vitas S, Bervar M, Taleska Stupica G, et al
    Perioperative Use of Pulmonary Artery Catheter in a Patient With Severe Chronic Thromboembolic Pulmonary Hypertension Undergoing Major Gynecological Surgery: A Case Report.
    Cureus. 2026;18:e103094.
    PubMed    
    Abstract available
    
    

62. HIROSE M, Nakano Y, Adachi S, Sugiyama T, et al
    Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.
    Circ Rep. 2025;8:486-494.
    PubMed    
    Abstract available
    
    

63. ZISMAN D, Sahay S, Bandyopadhyay D, Al-Astal A, et al
    Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study.
    Adv Ther. 2026 Mar 10. doi: 10.1007/s12325-026-03508.
    PubMed    
    Abstract available
    
    

64. ZHAO Q, Su S, Chen J, Huayu M, et al
    Kaempferol alleviates right ventricular hypertrophy in high-altitude pulmonary hypertension rats by modulating the AMPK/ACC/CPT1B axis and the AMPK-mediated LDHA/PDHA1 pathway.
    Food Funct. 2026 Mar 10. doi: 10.1039/d5fo04265.
    PubMed    
    Abstract available
    
    

65. KHILZI K, Blanco I, Piccari L, Barbera JA, et al
    Smoking exposure on diagnosis and survival of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from REHAP registry.
    Pulmonology. 2026;32:2640669.
    PubMed    
    Abstract available
    
    

66. LACHANT D, Agarwal N, Norton K, Haight D, et al
    Longitudinal Remote 6-Minute Walk Distance and Cardiac Effort Using Wearable Sensors in Pulmonary Hypertension.
    Pulm Circ. 2026;16:e70278.
    PubMed    
    Abstract available
    
    

67. TARRAS ES, Murayama A, Singh I, Freeman LM, et al
    Industry Payments and Prescribing Patterns of Pulmonary Hypertension Therapies in the United States.
    Pulm Circ. 2026;16:e70279.
    PubMed    
    Abstract available
    
    

68. CHENG Q, Yang F, Wu C, Xiao D, et al
    Machine learning-based predictive model for the diagnosis of PH pulmonary hypertension diagnosis integrating cardiac magnetic resonance imaging and clinical biomarkers.
    BMC Med Imaging. 2026 Mar 9. doi: 10.1186/s12880-026-02254.
    PubMed    
    
    
    

69. MULAWARMAN R, Ongko Joyo E, Aefiansyah Putra MA, Agita Sembiring A, et al
    Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension.
    Egypt Heart J. 2026;78:15.
    PubMed    
    Abstract available
    
    

70. SUBRAMANIAM J, Jonnakuti V, Collum SD, Martineau S, et al
    Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics.
    Br J Biomed Sci. 2026;83:15687.
    PubMed    
    Abstract available
    
    

71. CENDALI FI, Lisk C, Argabright A, Dzieciatkowska M, et al
    Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension.
    Hemasphere. 2026;10:e70318.
    PubMed    
    Abstract available
    
    

72. QIN X, Zheng L, Zhao H, Li Q, et al
    Identification of circulating microRNA biomarkers in pulmonary hypertension of group 2 for early detection.
    Front Cardiovasc Med. 2026;13:1704427.
    PubMed    
    Abstract available
    
    

73. MOUSTAFA M, Gopal H, Minnock C, Gaine S, et al
    Rectus sheath block a retrospective review of a novel adjunct for treatment of the injection site pain associated with treprostinil subcutaneous infusion in pulmonary hypertension case series.
    Pain Manag. 2026 Mar 9:1-7. doi: 10.1080/17581869.2026.2641557.
    PubMed    
    Abstract available
    
    

74. FUJIWARA M, Yamamura A, Kondo R, Suzuki Y, et al
    Therapeutic effects of fingolimod through sphingosine-1-phosphate signaling in pulmonary arterial hypertension.
    J Pharmacol Sci. 2026;160:191-198.
    PubMed    
    Abstract available
    
    

75. LI X, Mao Z, Wang C, Liu Y, et al
    Intervention effect of small extracellular vesicles derived from dental pulp stem cells on a high-altitude pulmonary edema model in male rats.
    Physiol Rep. 2026;14:e70810.
    PubMed    
    Abstract available
    
    

76. KEMPTON H, Olsen N, Kearney K, Hayward CS, et al
    The resistance-compliance relationship at low pulmonary resistance: Integrating pulmonary wedge pressure into right ventricular load assessment.
    Physiol Rep. 2026;14:e70811.
    PubMed    
    Abstract available
    
    

77. CUI H, Min F, Deng H, Wang Y, et al
    Leonurine ameliorates hypoxic pulmonary hypertension by inhibiting cross-talk between neutropHils and endothelial cells via SERPINB3 targeting.
    Int Immunopharmacol. 2026;176:116467.
    PubMed    
    Abstract available
    
    

78. WANG Y, Shen R, Liu Y
    Impact of pulmonary-artery-to-aorta ratio on clinical outcomes in patients undergoing transcatheter aortic valve implantation: A retrospective study.
    Sci Prog. 2026;109:368504261431852.
    PubMed    
    Abstract available
    
    

79. CHEN R, Liu C, Han J, Dong J, et al
    Paradigm shift: from pulmonary vasodilation to cardiopulmonary dual-track therapy-a comprehensive review of pathophysiology and advances in pulmonary hypertension-associated right heart failure.
    Respir Res. 2026 Mar 7. doi: 10.1186/s12931-026-03594.
    PubMed    
    
    
    

80. CAO Z, Ma W, Liu C
    Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights.
    Cardiovasc Drugs Ther. 2026 Mar 6. doi: 10.1007/s10557-026-07859.
    PubMed    
    Abstract available
    
    

81. OGUNTADE AS, Ogah OS, Adebiyi AA, Oladokun B, et al
    Right ventricular function, pulmonary hypertension and incident mortality in heart failure: Insights from a West-African cohort.
    Cardiovasc J Afr. 2025;36:309-322.
    PubMed    
    Abstract available
    
    

82. KARACA BAYSAL P, Urkut N, Girgin Dinc E, Gurcu ME, et al
    Emergency cesarean section in pregnant women with severe pulmonary hypertension: the potential role of extracorporeal life support.
    Ulus Travma Acil Cerrahi Derg. 2026;32:177-183.
    PubMed    
    Abstract available
    
    

83. SUZUKI Y, Ramadhiani R, Ryanto GRT, Musthafa A, et al
    Loss of Endothelin-2 in Pulmonary Neuroendocrine Cells Promotes the Development of Hypoxia-induced Pulmonary Hypertension.
    Clin Sci (Lond). 2026 Mar 3:CS20250135. doi: 10.1042/CS20250135.
    PubMed    
    Abstract available
    
    

84. NOGUCHI Y, Miyake M, Mima H, Matsutani H, et al
    Usefulness of exercise stress echocardiography to identify masked pulmonary hypertension associated with hyperthyroidism.
    J Cardiol Cases. 2025;33:75-77.
    PubMed    
    Abstract available
    
    

85. WANG R, Tan J, Li G, Pan Z, et al
    Development and internal validation of a machine learning-based prediction model for pulmonary hypertension in COPD.
    Front Med (Lausanne). 2026;13:1752113.
    PubMed    
    Abstract available
    
    

86. MUNOZ-BONET JI, Sebastian-Cuevas FJ, Flor-Macian EM, Ortega-Sanchez MDC, et al
    Hypercapnia as a Key Mechanism in the Development of Pulmonary Hypertension in Malignant Pertussis: A Case Report.
    Respirol Case Rep. 2026;14:e70528.
    PubMed    
    Abstract available
    
    

87. ANDRYAN DP, Hasanah DY, Atmadikoesoemah CA
    The potential effect of calcium sensitizer in pulmonary hypertension post-coronavirus disease-19 infection in presumptive familial dilated cardiomyopathy: a case report.
    J Med Case Rep. 2026 Mar 5. doi: 10.1186/s13256-026-05854.
    PubMed    
    Abstract available
    
    

88. KHALIL F, Asleh R, Mawer S, Kim K, et al
    Interplay of Pulmonary Hypertension and the Effects of Panel-Reactive Antibodies on Outcomes of Heart Transplant Recipients Bridged With Left Ventricular Assist Device.
    J Am Heart Assoc. 2026 Mar 4:e044572. doi: 10.1161/JAHA.125.044572.
    PubMed    
    Abstract available
    
    

89. BUNCLARK K, Newman J, Ghani H, Munagala S, et al
    The Pulmonary Hypertension Global Patient Survey: Groups 2 and 3.
    Pulm Circ. 2026;16:e70256.
    PubMed    
    Abstract available
    
    

90. QUYAM S, Drumm S, Mungala S, Bunclark K, et al
    The Pulmonary Hypertension Global Patient Survey: Understanding the Invisible Burden of Paediatric Pulmonary Hypertension.
    Pulm Circ. 2026;16:e70269.
    PubMed    
    Abstract available
    
    

91. BUNCLARK K, Newman J, Ghani H, Munagala S, et al
    The Pulmonary Hypertension Global Patient Survey: Physical and Psychosocial Impacts on Health-Related Quality of Life.
    Pulm Circ. 2026;16:e70264.
    PubMed    
    Abstract available
    
    

92. WANG E, Palaskas NL, Sahay S, Yu W, et al
    Tumoural emboli syndromes case series: diagnostic dilemma in patients with cancer and pulmonary hypertension.
    Eur Heart J Case Rep. 2026;10:ytag079.
    PubMed    
    
    
    

93. GILLEY J, Shivanna B
    The relationship between cobalamin C deficiency and unexplained pediatric pulmonary hypertension.
    Pediatr Res. 2026 Mar 3. doi: 10.1038/s41390-026-04899.
    PubMed    
    
    
    

94. EILON E, Lishinsky-Fischer N, Levy J
    Response to: 'Comment on 'Systemic prostacyclin analogues in pulmonary hypertension are associated with reduced risk of age-related macular degeneration: a cohort study".
    Eye (Lond). 2026 Mar 3. doi: 10.1038/s41433-026-04379.
    PubMed    
    
    
    

95. MAN HJ, Zhao YD, Asghar U, Wu L, et al
    Distinct endothelial cells in chronic thromboembolic pulmonary hypertension.
    NPJ Cardiovasc Health. 2025;2:33.
    PubMed    
    Abstract available
    
    

96. ZHAO D, Li Y, Yang Y, Yu F, et al
    An optimized machine learning model based on hematological indicators for the noninvasive identification of baicalin's therapeutic effects in pulmonary hypertension.
    Comput Methods Biomech Biomed Engin. 2026.
    PubMed    
    Abstract available
    
    

97. WERNER RA, Higuchi T
    In vivo targeting of fibroblast activation in chronic thromboembolic pulmonary hypertension: Ready for pulmonary prime time?
    J Nucl Cardiol. 2026;56:102588.
    PubMed    
    
    
    

98. LIANG Q, Gou H, Zhu Y, He L, et al
    Inhibiting the pathological changes of PASMCs is an effective approach for medicinal plants or secondary metabolites in treating pulmonary hypertension.
    Front Pharmacol. 2026;17:1725809.
    PubMed    
    Abstract available
    
    

99. MIRDAMADI A, Adib-Hajbagheri P
    Misleading echocardiographic artifact mimicking severe pulmonary hypertension in a pregnant woman: A diagnostic challenge.
    Respir Med Case Rep. 2026;60:102374.
    PubMed    
    Abstract available
    
    

100. LIU BY, Yan WJ, Chen Y, Zhang HW, et al
     The Prognostic Accuracy of Three-Dimensional Echocardiography in Patients With Pre-Capillary Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70260.
     PubMed    
     Abstract available
     
     

101. NEVAREZ GILBERT AB, Bischoff AR
     Pulmonary Hypertension in Infants Who Are Premature.
     Neoreviews. 2026;27:e144-e156.
     PubMed    
     Abstract available
     
     

102. RESQUETI V, Torres-Castro R, Gimeno-Santos E, Lopes Cardoso N, et al
     Limitations of 6-minute walk test-based equations in predicting peak oxygen uptake and risk assessment in patients with pulmonary hypertension and COPD.
     Respir Med. 2026;254:108738.
     PubMed    
     Abstract available
     
     

103. VILLEGAS-ESGUEVILLAS M, Barreira B, Hernandez-Garcia A, Adao R, et al
     The Sigma-1 receptor agonist PRE084 improves cardiopulmonary function and remodelling in an experimental model of pulmonary arterial hypertension.
     Biomed Pharmacother. 2026;196:119115.
     PubMed    
     Abstract available
     
     

104. GAO D, Song S, Gao Y, Zhu X, et al
     Silencer-regulated circLSM14A inhibits autophagy of pulmonary artery smooth muscle cells through parental protein LSM14A.
     Free Radic Biol Med. 2026;247:502-515.
     PubMed    
     Abstract available
     
     

105. D'ALTO M, Scelsi L, Giuliani L, Perna GP, et al
     Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO).
     Vascul Pharmacol. 2026;162:107585.
     PubMed    
     Abstract available
     
     

106. JOSE A, Elwing JM
     Management of hepatopulmonary syndrome and portopulmonary hypertension.
     Curr Opin Crit Care. 2026;32:187-192.
     PubMed    
     Abstract available
     
     

107. QIAN X, Deng Y, Guo T, Huang X, et al
     Plasma non-targeted metabolomics unveils the metabolic signatures of trans-right ventricle in pulmonary arterial hypertension associated with atrial septal defect.
     Clin Chim Acta. 2026;584:120849.
     PubMed    
     Abstract available
     
     

108. BOLAND E, Freeman MG, Corcoran DS, Ford TJ, et al
     Coronary pathophysiology in idiopathic pulmonary arterial hypertension.
     JCI Insight. 2026;11:e194613.
     PubMed    
     Abstract available
     
     

109. CANTU-MARTINEZ O, Fudim M, Kong DF, Tedford RJ, et al
     Accuracy of site versus core laboratory interpretations of right heart catheterization hemodynamics.
     Am Heart J. 2026;295:107351.
     PubMed    
     Abstract available
     
     

110. POLINI B, Ghelardoni S, Capone G, Monti E, et al
     Circulating microRNAs in pulmonary arterial hypertension: biomarkers for diagnosis, prognostic stratification, and treatment.
     Geroscience. 2026;48:2243-2266.
     PubMed    
     Abstract available
     
     

111. WU SE, Mazurek JA, Mayeux JD, Habib NG, et al
     Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH).
     Pulm Pharmacol Ther. 2026;92:102406.
     PubMed    
     Abstract available
     
     

112. CHEN HM, Hou P, Liang SH, Guo WL, et al
     The Prognostic Value of (18)F-FAPI PET/CT Imaging in Pulmonary Arterial Hypertension.
     JACC Cardiovasc Imaging. 2026;19:363-374.
     PubMed    
     Abstract available
     
     

113. SAGAR P, Thejaswi P, Karthikeyan M, Sivakumar K, et al
     Custom-Fenestrated Atrial Septal Occluder Devices in Borderline Patients With Pulmonary Arterial Hypertension or Restrictive Left Ventricular Physiology.
     Catheter Cardiovasc Interv. 2026;107:1156-1169.
     PubMed    
     Abstract available
     
     

114. GARCIA DELGADO GM, Shammi UA, Thornburgh C, Ruppel M, et al
     Dynamic RBC-To-Membrane Ratio in (129)Xe MRI: A Biomarker of Decreased Lung Function in Pulmonary and Vascular Diseases.
     Magn Reson Med. 2026;95:2500-2507.
     PubMed    
     Abstract available
     
     

115. MANZI G, Maggio E, Recchioni T, Adamo FI, et al
     The pleiotropic effects of sotatercept.
     Vascul Pharmacol. 2026;162:107577.
     PubMed    
     Abstract available
     
     

116. RYAN JJ, Wilson M, Saggar R, Benninger C, et al
     Expert consensus on patient engagement strategies for improving patient activation and shared decision making in pulmonary arterial hypertension.
     J Am Assoc Nurse Pract. 2026;38:136-145.
     PubMed    
     Abstract available
     
     

117. WONG JM, Lai E, Brent BN, Schiller NB, et al
     Noninvasive Assessment of Mean Pulmonary Artery Pressure: A Comparison of Doppler Echocardiographic Methods.
     J Am Soc Echocardiogr. 2026;39:294-303.
     PubMed    
     Abstract available
     
     

118. QIU LH, Wang PR, Zhang K, Ning XH, et al
     The application of partial pressure of oxygen adjusted indirect Fick method in vasoreactivity testing by inhaling oxygen in congenital heart disease.
     Hypertens Res. 2026;49:874-882.
     PubMed    
     Abstract available
     
     

119. XU H, Ye L, Du C, Tang H, et al
     EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
     Eur Heart J. 2025 Sep 25:ehaf763. doi: 10.1093.
     PubMed    
     Abstract available
     
     

120. PEIXOTO J, Neto J, Pissarra S, Azevedo I, et al
     Giant Omphalocele: Systematic Review of Pulmonary Complications and Implications for Neonatal Care.
     Eur J Pediatr Surg. 2025 Jul 17. doi: 10.1055/a-2649-0781.
     PubMed    
     Abstract available
     
     

121. SHEN Z, Huang D, Jia N, Zhao S, et al
     Protective effects of Eleutheroside E against high-altitude pulmonary edema by inhibiting NLRP3 inflammasome-mediated pyroptosis.
     Biomed Pharmacother. 2023;167:115607.
     PubMed    
     Abstract available
     
     

122. SOARES LL, Leite LB, Ervilha LOG, Pelozin BRA, et al
     Resistance exercise training benefits pulmonary, cardiac, and muscular structure and function in rats with stable pulmonary artery hypertension.
     Life Sci. 2023;332:122128.
     PubMed    
     Abstract available
     
     

123. GUO WL, Hou P, Tan WG, Lei YX, et al
     [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy].
     Zhonghua Jie He He Hu Xi Za Zhi. 2023;46:1014-1018.
     PubMed    
     Abstract available
     
     

124. LI L, Xue Q, Zhang M, Yang Z, et al
     Upregulation of the key biomarker kinesin family member 20A (KIF20A) is associated with pulmonary artery hypertension.
     Genomics. 2023;115:110705.
     PubMed    
     Abstract available
     
     

125. TAKAI A, Yamagishi M, Ikeda K, Sugimoto A, et al
     Effectiveness of cardiac palliative surgery for trisomy 18 patients with increased pulmonary blood flow.
     Am J Med Genet A. 2023;191:2703-2710.
     PubMed    
     Abstract available
     
     

126. TAMURA Y, Kumamaru H, Nishimura S, Nakajima Y, et al
     Initial Triple Combination Therapy Including Intravenous Prostaglandin I(2) for the Treatment of Patients with Severe Pulmonary Arterial Hypertension.
     Int Heart J. 2023;64:684-692.
     PubMed    
     Abstract available
     
     

127. RICHTER MJ, Douschan P, Fortuni F, Gall H, et al
     Echocardiographic pressure-strain loop-derived stroke work of the right ventricle: validation against the gold standard.
     ESC Heart Fail. 2023;10:3209-3215.
     PubMed    
     Abstract available
     
     

128. BAGGA A, Astavans A, Goldin G, Everitt IK, et al
     National Patterns of Pulmonary Hypertension Mortality in the United States, 2010-2024.
     Am J Cardiol. 2026 Mar 3:S0002-9149(26)00117.
     PubMed    
     
     
     

129. MOOERS EA, Rana U, Joshi CN, Afolayan AJ, et al
     Decreased AMP-Kinase Function in Pulmonary Artery Smooth Muscle Cells Contributes to Pulmonary Artery Remodeling in Persistent Pulmonary Hypertension of Newborn.
     Am J Physiol Lung Cell Mol Physiol. 2026 Feb 25. doi: 10.1152/ajplung.00229.2025
     PubMed    
     Abstract available
     
     

130. RICHALET JP, Jeny F, Callard P, Bernaudin JF, et al
     High-altitude pulmonary edema: the intercellular network hypothesis.
     Am J Physiol Lung Cell Mol Physiol. 2023;325:L155-L173.
     PubMed    
     Abstract available
     
     

131. CHEN CN, Hajji N, Yeh FC, Rahman S, et al
     Restoration of Foxp3(+) Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology.
     Am J Respir Crit Care Med. 2023;208:879-895.
     PubMed    
     Abstract available
     
     

132. BIRD EM, Yang JZ, Mims EW, Kerr KM, et al
     Safety and Immediate Efficacy of Pulmonary Thromboendarterectomy for Chronic Thromboembolic Disease.
     Ann Thorac Surg. 2025 Jun 17:S0003-4975(25)00529.
     PubMed    
     Abstract available
     
     

133. ROTER KW, Agrawal V
     Decoding Exercise Pulmonary Hypertension: A Noninvasive Blueprint for Detection in Chronic Thromboembolic Pulmonary Disease.
     Chest. 2026;169:584-585.
     PubMed    
     
     
     

134. JOHN T, Neuhuber L, Douschan P, Foris V, et al
     The Clinical Relevance of Unclassified Pulmonary Hypertension.
     Chest. 2026 Mar 9:S0012-3692(26)00275-8. doi: 10.1016/j.chest.2025.
     PubMed    
     
     
     

135. LAMMI MR, Khan SL, Rao Y, Zhao W, et al
     The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension.
     Chest. 2026 Mar 7:S0012-3692(26)00287-4. doi: 10.1016/j.chest.2026.
     PubMed    
     Abstract available
     
     

136. PRADHAN NM, Wessler BS, Hill N, Kurz S, et al
     The Mitral Valve and The Lungs.
     Chest. 2025 Nov 24:S0012-3692(25)05795-2. doi: 10.1016/j.chest.2025.
     PubMed    
     Abstract available
     
     

137. BRONCANO J, Shifren A, Royuela J, Bhalla S, et al
     Role of MRI in Interstitial Lung Diseases.
     Chest. 2026;169:698-709.
     PubMed    
     Abstract available
     
     

138. WANG AY, Ma JL, Cui Y, Qiu BC, et al
     Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension.
     Chest. 2026;169:758-768.
     PubMed    
     Abstract available
     
     

139. JOKI Y, Konishi H, Takasu K, Katsuumi G, et al
     Parathyroid Hormone Contributes to Pulmonary Hypertension in Hypoxic Conditions.
     Circ Res. 2026 Mar 4. doi: 10.1161/CIRCRESAHA.125.327401.
     PubMed    
     Abstract available
     
     

140. RAGHU G, Sahay S, Price LC, Weatherald J, et al
     Pulmonary Hypertension Associated With Interstitial Lung Disease: State-of-the-Art Review.
     Eur Respir J. 2026 Mar 12:2502651. doi: 10.1183/13993003.02651-2025.
     PubMed    
     Abstract available
     
     

141. KHAN MS, Borlaug BA, Butler J, Gomberg-Maitland M, et al
     Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions.
     J Am Coll Cardiol. 2026 Mar 11:S0735-1097(26)00134.
     PubMed    
     Abstract available
     
     

142. SARDO S, Tripodi VF, Guerzoni F, Musu M, et al
     Pulmonary Vasodilator and Inodilator Drugs in Cardiac Surgery: A Systematic Review With Bayesian Network Meta-Analysis.
     J Cardiothorac Vasc Anesth. 2023;37:2261-2271.
     PubMed    
     Abstract available
     
     

143. LUO D, Zheng X, Yang Z, Li H, et al
     Machine learning for clustering and postclosure outcome of adult CHD-PAH patients with borderline hemodynamics.
     J Heart Lung Transplant. 2023;42:1286-1297.
     PubMed    
     Abstract available
     
     

144. BYRD CE, Wren JT Jr, Desiraju S, McNamara PJ, et al
     A hemodynamic-driven approach to chronic pulmonary hypertension in congenital diaphragmatic hernia.
     J Perinatol. 2026 Feb 23. doi: 10.1038/s41372-026-02582.
     PubMed    
     Abstract available
     
     

145. CALE R, Ferreira F, Martinho M, Alegria S, et al
     Residual physiological abnormalities after pulmonary endarterectomy and balloon pulmonary angioplasty in CTEPH.
     PLoS One. 2026;21:e0344192.
     PubMed    
     Abstract available
     
     

146. KAWAKAMI T, Hosokawa S, Ito M, Kurozumi A, et al
     PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes.
     PLoS One. 2026;21:e0344084.
     PubMed    
     Abstract available